6,892 Shares in Medtronic PLC $MDT Acquired by Englebert Financial Advisers LLC

Englebert Financial Advisers LLC bought a new position in shares of Medtronic PLC (NYSE:MDT) during the fourth quarter, Holdings Channel reports. The fund bought 6,892 shares of the medical technology company’s stock, valued at approximately $662,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Artisan Partners Limited Partnership increased its holdings in shares of Medtronic by 2.6% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock worth $117,579,000 after buying an additional 31,314 shares during the last quarter. SageView Advisory Group LLC increased its holdings in shares of Medtronic by 164.8% in the 3rd quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock worth $2,305,000 after buying an additional 15,062 shares during the last quarter. CSM Advisors LLC increased its holdings in shares of Medtronic by 13.2% in the 3rd quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock worth $27,169,000 after buying an additional 33,167 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Medtronic by 65.8% in the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after buying an additional 54,898 shares during the last quarter. Finally, Applied Finance Capital Management LLC bought a new position in shares of Medtronic in the 3rd quarter worth $1,308,000. Institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

MDT has been the topic of a number of research analyst reports. JPMorgan Chase & Co. decreased their price target on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. CICC Research initiated coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “outperform” rating on the stock. Daiwa Securities Group decreased their price target on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Weiss Ratings lowered shares of Medtronic from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, April 21st. Finally, UBS Group decreased their price target on shares of Medtronic from $104.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, April 22nd. Fifteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $107.80.

Medtronic Trading Down 2.1%

Shares of MDT opened at $74.56 on Tuesday. The stock has a market capitalization of $95.73 billion, a P/E ratio of 20.77, a PEG ratio of 1.81 and a beta of 0.62. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The firm has a fifty day simple moving average of $86.40 and a two-hundred day simple moving average of $94.14. Medtronic PLC has a twelve month low of $74.40 and a twelve month high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.57 EPS for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were given a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.8%. Medtronic’s dividend payout ratio is presently 79.11%.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.26% of the stock is owned by insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).